Impact of Diabetes and Glycemia on Cardiac Improvement and Adverse Events Following Mechanical Circulatory Support
Authors:
- Christos P. KyriakopoulosChristos P. Kyriakopoulos
- Iosif TalebITIosif Taleb
- Eleni TseliouETEleni Tseliou
- Konstantinos SiderisKSKonstantinos Sideris
- Rana HamoucheRHRana Hamouche
- Eleni ManetaEMEleni Maneta
- Ethan KrauspeEKEthan Krauspe
- Sean SelkoSSSean Selko
- Joseph R. ViskerJoseph R. Visker
- Elizabeth DranowEDElizabeth Dranow
- Matthew L. GoodwinMGMatthew L. Goodwin
Open Access
- 16 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (14) , e032936
Abstract
Background: Type 2 diabetes is prevalent in cardiovascular disease and contributes to excess morbidity and mortality. We sought to investigate the effect of glycemia on functional cardiac improvement, morbidity, and mortality in durable left ventricular assist device (LVAD) recipients. Methods and Results: Consecutive patients with an LVAD were prospectively evaluated (n=531). After excluding patients missing pre‐LVAD glycated hemoglobin (HbA1c) measurements or having inadequate post‐LVAD follow‐up, 375 patients were studied. To assess functional cardiac improvement, we used absolute left ventricular ejection fraction change (ΔLVEF: LVEF post‐LVAD−LVEF pre‐LVAD). We quantified the association of pre‐LVAD HbA1c with ΔLVEF as the primary outcome, and all‐cause mortality and LVAD‐related adverse event rates (ischemic stroke/transient ischemic attack, intracerebral hemorrhage, gastrointestinal bleeding, LVAD‐related infection, device thrombosis) as secondary outcomes. Last, we assessed HbA1c differences pre‐ and post‐LVAD. Patients with type 2 diabetes were older, more likely men suffering ischemic cardiomyopathy, and had longer heart failure duration. Pre‐LVAD HbA1c was inversely associated with ΔLVEF in patients with nonischemic cardiomyopathy but not in those with ischemic cardiomyopathy, after adjusting for age, sex, heart failure duration, and left ventricular end‐diastolic diameter. Pre‐LVAD HbA1c was not associated with all‐cause mortality, but higher pre‐LVAD HbA1c was shown to increase the risk of intracerebral hemorrhage, LVAD‐related infection, and device thrombosis by 3 years on LVAD support ( P P <0.001). Conclusions: Type 2 diabetes and pre‐LVAD glycemia modify the potential for functional cardiac improvement and the risk for adverse events on LVAD support. The degree and duration of pre‐LVAD glycemic control optimization to favorably affect these outcomes warrants further investigation.Keywords
This publication has 53 references indexed in Scilit:
- The pyruvate-lactate axis modulates cardiac hypertrophy and heart failureCell Metabolism, 2021
- Diabetes Mellitus Is Not a Risk Factor for Patients Supported With Left Ventricular Assist DeviceThe Annals of Thoracic Surgery, 2020
- Outcomes of Patients after Successful Left Ventricular Assist Device Explantation: A EUROMACS StudyESC Heart Failure, 2020
- Influence of Diabetes Mellitus on Outcomes in Patients After Left Ventricular Assist Device ImplantationThe Annals of Thoracic Surgery, 2018
- Left Ventricular Assist Device Implantation Improves Glycaemic Control: A Systematic Review and Meta-AnalysisESC Heart Failure, 2018
- Outcomes for Patients With Diabetes After Continuous-Flow Left Ventricular Assist Device ImplantationJournal of Cardiac Failure, 2016
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Insulin resistance and heart failureCurrent Heart Failure Reports, 2009
- Insulin Resistance and Risk of Congestive Heart FailureJAMA, 2005
- Diabetes and cardiovascular disease. The Framingham studyJAMA, 1979